Mozart Therapeutics Presents Compelling New Preclinical Data on MTX-201 at the 2025 Crohn’s and Colitis Congress® (PR Newswire)

Could a bispecific antibody revolutionize inflammatory bowel disease (IBD) treatment? Mozart Therapeutics is presenting new preclinical data on MTX-201, an immune-modulating therapy that selectively targets CD8 regulatory T cells (Treg) to reduce inflammation and epithelial damage in IBD patients.